Therapeutics News and Research

RSS

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

Xcovery, a developer of targeted therapeutics for ALK+ non-small cell lung cancer (NSCLC) is scheduled to present January 6th, 2016 at the fourth annual AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic, at the Hard Rock Hotel, in San Diego, CA.

5 Jan 2016

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Ionis Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to IONIS-HTTRx for the treatment of patients with Huntington's disease (HD).

5 Jan 2016

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers.

5 Jan 2016

Study reveals promising mechanism for attacking Ebola virus

In late December, nearly two years after the epidemic began, the World Health Organization has declared the African country of Guinea to be free of Ebola virus infections. But, the race to find a cure and therapies to combat the disease are forging ahead as officials warn that inattention could lead to another epidemic.

5 Jan 2016

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

My laboratory’s long standing interest is the study of the signaling capabilities of stem cells, both under homeostatic conditions

From Beckman Coulter Life Sciences - Flow Cytometry 5 Jan 2016

Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

A nonsteroidal anti-inflammatory drug (NSAID) changed the composition and diversity of gut microbes, which in turn shaped how the drug is broken down and ultimately, cut its effectiveness, according to an animal study from the Perelman School of Medicine at the University of Pennsylvania.

5 Jan 2016

Numerous experts to attend Global Conference for Collaboration and Development on Regenerative Life Science in Beijing

In order to fulfill the mission of protecting life and health, and to inherit the advanced scientific technologies created by Dr. Rongxiang Xu in his lifetime and his spirit of healing the wounded and rescuing the dying, the Global Conference for Collaboration and Development on Regenerative Life Science cosponsored by The Chinese Red Cross Foundation and Beijing MEBO Institute for Burns, Wounds and Ulcers will be held in the Great Hall of the People in Beijing on Jan. 6, 2016.

4 Jan 2016

UT Southwestern scientists use new gene-editing technique to prevent progression of DMD in young mice

Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice.

4 Jan 2016

World's largest database for cancer drug discovery revolutionised by 3D techniques

THE world's largest database for cancer drug discovery has been revolutionised by adding 3D structures of faulty proteins and maps of cancer's communication networks, according to Cancer Research UK-funded research published in Nucleic Acid Research today (Monday).

4 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Amarantus BioScience Holdings, Inc., a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has requested Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the US Food and Drug Administration to treat GCMN with Engineered Skin Substitute (ESS).

30 Dec 2015

Body can control pathogen-induced inflammatory response, find Georgia State researchers

The body can control inflammatory response triggered by invasions of microbial pathogens, such as bacteria and viruses, a discovery that could lead to the development of new therapeutic agents for uncontrolled inflammation, according to researchers at Georgia State University.

29 Dec 2015

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies.

29 Dec 2015

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases.

24 Dec 2015

Study identifies genetic factors that play role in AMD

An international study has identified the number of genetic factors known to play a role in age-related macular degeneration (AMD), the worldwide leading cause of blindness in the elderly.

23 Dec 2015

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015

Nuvo reacquires development and marketing rights for Pliaglis

Nuvo Research Inc., a life sciences company with growing revenues and a diverse portfolio of topical products, today announced it has reacquired Pliaglis development and marketing rights for the U.S., Canada and Mexico.

22 Dec 2015

QMUL, Barts Health NHS Trust receive £10.2m to create new cardiovascular academic medical centre

Queen Mary University of London and Barts Health NHS Trust have received £10.2m from Barts Charity for the creation of a world-class cardiovascular academic medical centre at the Trust's Barts Heart Centre, St Bartholomew's Hospital.

22 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Forge Therapeutics, Inc., a biotechnology company developing innovative medicines using a breakthrough drug discovery platform targeting metalloproteins, announced today it has obtained an exclusive license from the University of California San Diego to patent rights related to novel metalloprotein inhibitors discovered in the laboratory of Forge Therapeutics scientific co-founder Professor Seth Cohen, Ph.D.

22 Dec 2015

Therapeutics News and Research

Xcovery to present data from X-396 Phase l/ll trial in patients with ALK+ NSCLC at AACR-IASLC conference

FDA grants Orphan Drug Designation to Ionis Pharmaceuticals' IONIS-HTT Rx for treatment of HD patients

Ardelyx announces positive results from RDX022 clinical study for treatment of hyperkalemia

Study reveals promising mechanism for attacking Ebola virus

Using stem cells to tackle CNS disorders: an interview with Dr Stefano Pluchino

Drug-microbe interactions may contribute to adverse effects, lessen effectiveness of NSAID

Numerous experts to attend Global Conference for Collaboration and Development on Regenerative Life Science in Beijing

UT Southwestern scientists use new gene-editing technique to prevent progression of DMD in young mice

World's largest database for cancer drug discovery revolutionised by 3D techniques

New oral breast cancer drug has potential to combat other types of cancer

Amarantus seeks FDA's Rare Pediatric Disease Designation and ODD to treat GCMN with Engineered Skin Substitute

Body can control pathogen-induced inflammatory response, find Georgia State researchers

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Study identifies genetic factors that play role in AMD

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Nuvo reacquires development and marketing rights for Pliaglis

QMUL, Barts Health NHS Trust receive £10.2m to create new cardiovascular academic medical centre

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Forge Therapeutics obtains exclusive license to patent rights related to novel metalloprotein inhibitors

Next-generation therapeutics eBook eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News